Valeant says ex-CEO Pearson remains a significant shareholder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
July 14, 2016 1:29 PM EDTWhile Valeant Pharmaceuticals (NYSE: VRX) continues to avoid trading on fundamentals three potential catalysts lie ahead for the company. Today, Wells Fargo bearish-leaning analyst David Maris provide his thoughts ahead of these events.
The 3 events are:
Friday (7/15) advisory panel documents should become available ahead of next Tuesdays (7/19) FDA advisory panel on brodalumab;next... More